Advances and Unmet Needs in Hepatocellular Carcinoma
Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma.
Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma (HCC).
According to Finn, a lot of the major advances in unresectable HCC have occurred in the past 3 years. Unresectable can be defined as a case that is not curative, including patients undergoing chemoembolization, patients receiving localized or regional treatment who will progress and become candidates for systemic treatment, and patients who presented with cases advanced enough to be treated with systemic treatment upfront.
While there will always be a need for more effective and less toxic treatments, the real knowledge gap exists in the lack of knowledge in how these drugs will perform outside of clinical trials. According to Finn, real-world datasets are needed to draw this conclusion.
FDA Supports Phase 3 Plan for Amezalpat in Hepatocellular Carcinoma
August 16th 2024The FDA has given positive feedback on the planned phase 3 study for the combination of amezalpat, atezolizumab, and bevacizumab in the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Read More
